Skip to main content
Venus Remedies Ltd. logo

Venus Remedies Ltd. — Investor Relations & Filings

Ticker · VENUSREM ISIN · INE411B01019 LEI · 335800PBHMB6GQMFN127 BSE.NS Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2024-03-23 Regulatory Filings
Country IN India
Listing BSE.NS VENUSREM

About Venus Remedies Ltd.

https://venusremedies.com/

Venus Remedies Ltd. is a research-driven organization specializing in the development and manufacturing of innovative pharmaceutical formulations. The company focuses on critical therapeutic segments, including antimicrobial resistance, oncology, neurology, orthopedics, and pain management. It operates advanced manufacturing facilities and maintains a dedicated research and development wing, the Venus Medicine Research Centre, which prioritizes the creation of novel drug delivery systems and solutions for multi-drug resistant infections. Its product portfolio features a diverse range of injectables and specialized treatments, such as Elores, aimed at addressing complex clinical needs. The company serves a global market, providing healthcare solutions through a commitment to scientific excellence and international regulatory standards.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 100% confidence The document contains only a digital signature block with no substantive content, financial data, or report information. It is extremely short (215 characters) and does not include any report or announcement text. This fits the criteria for a Regulatory Filing (RNS) as a fallback category for minimal or non-report filings without specific classification.
2024-03-23 English
Updates
Interim / Quarterly Report Classification · 100% confidence The document is titled as "Copy of Unaudited financial results for the period ended on 31.12.2023" and includes an Independent Auditor's Limited Review Report on Unaudited Quarter and Nine Months ended consolidated financial results. It references Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to interim financial reporting. The document contains detailed financial data for the quarter and nine months ended December 31, 2023, including revenue, expenses, profit, and other comprehensive income. The presence of detailed financial statements and the nature of the report as an unaudited quarterly and nine months financial result clearly identifies it as an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR).
2024-03-12 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Venus Remedies Ltd has secured Good Manufacturing Practices (GMP) approval from UNICEF. It is an update about a regulatory or operational milestone rather than a financial report or detailed filing. The text includes no financial statements, no management discussion of financial results, no voting results, no legal proceedings, no capital changes, and no executive changes. It is a formal announcement under SEBI Regulation 30, which requires disclosure of material events. The document length is about 6,513 characters, which is consistent with a press release. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-03-11 English
Updates
Regulatory Filings Classification · 95% confidence The document text is extremely short (66 characters) and contains only a digital signature with no substantive content or financial data. It does not contain any report, announcement, or detailed information. Given the lack of content, this is likely a regulatory filing or a certification-type document without financial data. According to the rules, such minimal content defaults to Regulatory Filings (RNS).
2024-03-08 English
Press Release
Capital/Financing Update Classification · 90% confidence The document is a press release issued by Venus Remedies Limited announcing the receipt of an incentive under the Production Linked Incentive (PLI) scheme. It is addressed to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content focuses on the company's achievement and incentive disbursement, without containing any financial statements, detailed financial analysis, or regulatory certifications. The document is approximately 5,214 characters long, which is relatively short and primarily serves as an announcement rather than a detailed report. Therefore, it fits best under the category of Capital/Financing Update (CAP) as it relates to a financial incentive impacting the company's capital or funding situation.
2024-03-06 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document contains an announcement addressed to stock exchanges (NSE and BSE) regarding the publication of unaudited financial results for the quarter ended 31 December 2023. It includes detailed financial data such as income from operations, net profit before and after tax, earnings per share, and other financial metrics for the quarter and nine months ended 31 December 2023. The results are unaudited and have been reviewed by the Audit Committee and approved by the Board of Directors. The document also references compliance with SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, specifically Regulation 33, which pertains to quarterly financial results. The document is not merely an announcement that a report is available but contains substantive financial data and analysis for the quarter. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-02-16 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.